$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018 [Report Updated: 10-07-2018]

Published by Global Markets Direct: 10 Jul 2018 | 214041 | In Stock

Introduction

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018

Summary

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. Ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 16 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 9 and 3 respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Infectious Disease and Women's Health which include indications Rheumatoid Arthritis, Gouty Arthritis (Gout), Psoriasis, Autoimmune Disorders, Diffuse Large B-Cell Lymphoma, Inflammation, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Kidney Disease (Chronic Renal Failure), Endometriosis, Hematological Tumor, Lupus Erythematosus, Lymphoma, Multiple Sclerosis, Myelodysplastic Syndrome, Pelvic Inflammatory Disease (Pelvic Infections), Psoriatic Arthritis and Waldenstrom Macroglobulinemia.

The latest report Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)

- The report reviews Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018 [Report Updated: 10-07-2018]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Overview

    Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

    Amgen Inc

    Astellas Pharma Inc

    AstraZeneca Plc

    Aurigene Discovery Technologies Ltd

    Bayer AG

    Beijing Hanmi Pharmaceutical Co Ltd

    Bristol-Myers Squibb Co

    Genentech Inc

    Merck & Co Inc

    Pfizer Inc

    Rigel Pharmaceuticals Inc

    TG Therapeutics Inc

    Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Drug Profiles

    AS-2444697 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BAY-1834845 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CA-4948 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ND-2110 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ND-2158 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ND-346 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    PF-06650833 MR - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    R-191 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    R-835 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit IRAK-4 for Inflammation - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit IRAK4 for Inflammation - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit IRAK4 for Inflammatory Diseases - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit IRAK4 for Rheumatoid Arthritis and B-Cell Lymphoma - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Products

    Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Product Development Milestones

    Featured News & Press Releases

    Jun 26, 2018: Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

    Jan 17, 2018: Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma

    Mar 30, 2017: Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting

    Apr 12, 2016: Rigel Announces Presentation on preclinical research project R191 at Upcoming American Association of Cancer Research (AACR) Conference

    Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-4948 at AACR Annual Meeting

    Nov 08, 2015: Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule IRAK4 Program at AACR-NCI-EORTC International Conference

    Apr 20, 2015: TG Therapeutics Presents Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research Annual Meeting

    Apr 18, 2015: Aurigene to Present its IRAK-4 Inhibitors Programs at AACR 2015

    Apr 14, 2015: Curis Announces Presentation of Data From IRAK-4 Program at AACR Annual Meeting

    Nov 12, 2012: Nimbus discovery presents preclinical data on highly selective IRAK4 inhibitors for the treatment of rheumatic diseases.

    Nov 12, 2012: Nimbus discovery presents preclinical data on highly selective IRAK4 inhibitors for the treatment of rheumatic diseases.

    Nov 07, 2011: Ligand Reports Positive Preclinical Data On IRAK4 Program At 2011 American College Of Rheumatology Annual Scientific Meeting

    Mar 10, 2011: Nimbus Discovery unveils first of its kind drug discovery paradigm; announces seed round co-led by bill gates.

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

214041 | GMDHC1585TDB

Number of Pages

51

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2016
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11....
21 Dec 2016 by Global Markets Direct USD $3,500 More Info
Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Review, H2 2016
Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Review, H2 2016SummaryGlobal Mark...
14 Dec 2016 by Global Markets Direct USD $3,500 More Info
Interleukin Genetics, Inc. (ILIU) - Medical Equipment - Deals and Alliances Profile
SummaryInterleukin Genetics Inc (Interleukin) is a molecular diagnostics company which develops and ...
14 Nov 2016 by Global Data USD $250 More Info
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016SummaryGlobal M...
09 Nov 2016 by Global Markets Direct USD $3,500 More Info
Interleukin Genetics, Inc. (ILIU) - Medical Equipment - Deals and Alliances Profile
SummaryInterleukin Genetics, Inc. (Interleukin) is a molecular diagnostics company which develops an...
21 Jul 2016 by Global Data USD $250 More Info
Interleukin Genetics, Inc. (ILIU) - Financial and Strategic SWOT Analysis Review
Interleukin Genetics, Inc. (ILIU) - Financial and Strategic SWOT Analysis Review provides you an in-...
24 May 2016 by Global Data USD $125 More Info
Interleukin Genetics, Inc. (ILIU) - Medical Equipment - Deals and Alliances Profile
SummaryInterleukin Genetics, Inc. (Interleukin) is a molecular diagnostics company. It develops and ...
02 May 2016 by Global Data USD $250 More Info
CEL-SCI Corporation (formerly Interleukin-2, Inc.) – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
SummaryMarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments r...
15 Apr 2016 by Marketline USD $350 More Info
Interleukin Genetics, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Project Synopsis:Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and In...
10 Mar 2016 by Marketline USD $350 More Info
Interleukin Genetics, Inc. (ILIU) - Medical Equipment - Deals and Alliances Profile
SummaryInterleukin Genetics, Inc. (Interleukin) is a molecular diagnostics company. It develops and ...
24 Feb 2016 by Global Data USD $250 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018 [Report Updated: 10-07-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data